ADCs: a marriage of biology and chemistry
Antibody drug conjugates represent a rapidly evolving field of targeted therapeutics and there is global interest in exploiting them as potentially safer and more effective therapeutic agents in the oncology market and other fields. Cynthia Wooge, Global Strategic Marketing, SAFC reviews their development
Research & Development
Masters of synthesis
Medicinal chemists take an initial lead compound and through systematic design work improve its potency, efficacy, and properties such as solubility and metabolism. The aim is to create a molecule that is effective, has few side-effects and can be scaled up, initially for clinical trials and subsequently for commercial manufacturing.